November 14, 2024 11:12 AM ESTUpdated November 14, 09:32 PM
R&D

New Zealand clears first clin­i­cal tri­al of epi­ge­net­ic edit­ing for he­pati­tis B

Lei Lei Wu

News Reporter

Tune Ther­a­peu­tics an­nounced Thurs­day that New Zealand health au­thor­i­ties are al­low­ing the com­pa­ny to study its ex­per­i­men­tal epi­ge­net­ic edit­ing ther­a­py for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times